Participant flow

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) · Source last updated 2026-02-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks

   id

   FG000

   title

   Trastuzumab Emtansine (T-DM1)

2. description

   paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments

   id

   FG001

   title

   Paclitaxel + Trastuzumab (TH)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         13

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      not sufficient to receive intervention

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         384

      2. group Id

         FG001

         num Subjects

         128

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         383

      2. group Id

         FG001

         num Subjects

         114

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         14

      type

      NOT COMPLETED

   title

   Allocation

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         7

      2. group Id

         FG001

         num Subjects

         6

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         67

      2. group Id

         FG001

         num Subjects

         7

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         16

      2. group Id

         FG001

         num Subjects

         4

      type

      not available for data collection

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         383

      2. group Id

         FG001

         num Subjects

         114

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         293

      2. group Id

         FG001

         num Subjects

         97

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         90

      2. group Id

         FG001

         num Subjects

         17

      type

      NOT COMPLETED

   title

   Follow-Up

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice